ABCAM PLC Director/PDMR Shareholding (1339K)
May 03 2022 - 6:41AM
UK Regulatory
TIDMABC
RNS Number : 1339K
ABCAM PLC
03 May 2022
For immediate release
03 May 2022
ABCAM PLC
("Abcam" or the "Company")
Director/PDMR Shareholding Notification
Cambridge, UK: Abcam plc (Nasdaq: ABCM; AIM: ABC), a global
leader in the supply of life science research tools, has been
notified of the following dealings in Abcam's shares by certain
Directors of the Company as follows:
-- Sally W. Crawford, Non-Executive Director, purchased 13,141
American Depositary Receipts at a price of US$15.361 on Thursday 28
April 2022 and 1,859 American Depositary Receipts at a price of
US$15.7165 on Friday 29 April 2022.
The notification for Ms Crawford can be found below.
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Ms Sally W. Crawford
------------------------------- --------------------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------------------------
a) Position/status Non-Executive Director
------------------------------- --------------------------------------------------------
b) Initial notification Initial Notification
/Amendment
------------------------------- --------------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------------------
a) Name Abcam plc
------------------------------- --------------------------------------------------------
b) Legal Entity Identifier 213800B9N83DSNT33F79
------------------------------- --------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-----------------------------------------------------------------------------------------
a) Description of the financial American Depositary Shares
instrument, type of
instrument
US0003802040/ABCM
Identification code
------------------------------- --------------------------------------------------------
b) Nature of the transaction Purchase
------------------------------- --------------------------------------------------------
c) Currency USD
------------------------------- --------------------------------------------------------
d) Price(s) and volume(s) Price(s) Volume(s)
------------------- -----------------------------------
USD$15.361 13,141
-------------------------------------------------------- -----------------------------------
USD$15.7165 1,859
-------------------------------------------------------- -----------------------------------
e) Aggregated information Price(s) Aggregated Volume(s) Aggregated
Acquisition of shares Total
on release of award
Sales of shares to satisfy
income tax, national
insurance and dealing
charges
------------------------------- --------------- ----------------------- --------------
USD$15.4051 15,000 $231,075.87
---------------------------------------------------- ----------------------- --------------
f) Date of the transaction 28 and 29 April 2022
------------------------------- --------------------------------------------------------
g) Place of the transaction The Nasdaq Global Select Market
------------------------------- --------------------------------------------------------
Forward-Looking Statements
This announcement contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Any express or implied statements contained in this announcement
that are not statements of historical fact may be deemed to be
forward-looking statements, including, without limitation,
statements regarding award eligibility and LTIP issuance and value
sufficiency under the laws of the United Kingdom, as well as
statements that include the words "expect," "intend," "plan,"
"believe," "project," "forecast," "estimate," "may," "should,"
"anticipate" and similar statements of a future or forward-looking
nature. Forward-looking statements are neither promises nor
guarantees, but involve known and unknown risks and uncertainties
that could cause actual results to differ materially from those
projected, including, without limitation: a regional or global
health pandemic, including the novel coronavirus ("COVID-19"),
which has adversely affected elements of our business, could
severely affect our business, including due to impacts on our
operations and supply chains; challenges in implementing our
strategies for revenue growth in light of competitive challenges;
developing new products and enhancing existing products, adapting
to significant technological change and responding to the
introduction of new products by competitors to remain competitive;
failing to successfully identify or integrate acquired businesses
or assets into our operations or fully recognize the anticipated
benefits of businesses or assets that we acquire; if our customers
discontinue or spend less on research, development, production or
other scientific endeavours; and the important factors discussed
under the caption "Risk Factors" in Abcam's prospectus pursuant to
Rule 424(b) filed with the U.S. Securities and Exchange Commission
("SEC") on 22 October 2020, which is on file with the SEC and is
available on the SEC website at www.sec.gov, as such factors may be
updated from time to time in Abcam's other filings with the SEC.
Any forward-looking statements contained in this announcement speak
only as of the date hereof and accordingly undue reliance should
not be placed on such statements. Abcam disclaims any obligation or
undertaking to update or revise any forward-looking statements
contained in this announcement, whether as a result of new
information, future events or otherwise, other than to the extent
required by applicable law.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFXLFBLELXBBV
(END) Dow Jones Newswires
May 03, 2022 07:41 ET (11:41 GMT)
Abcam (LSE:ABC)
Historical Stock Chart
From Apr 2024 to May 2024
Abcam (LSE:ABC)
Historical Stock Chart
From May 2023 to May 2024